Abstract
Type 2 diabetes mellitus is a major and increasingly prevalent independent risk factor for cardiovascular morbidity and mortality worldwide. Glycemic control is a target of therapy and a principal marker of therapeutic success in diabetes, but whether lowering glucose is accompanied by a commensurate reduction in cardiovascular risk is a matter of ongoing controversy. It has become increasingly apparent from recent large-scale clinical outcome trials that glucose lowering is a poor predictor of cardiovascular outcome, and several instances of unexpectedly increased cardiovascular risk with antihyperglycemic drugs have sounded the alarm with regulatory agencies. This article reviews the critical facts that have led to a recent shift in the regulation of glucose-lowering drugs and makes the case for why new and existing antidiabetic medications should be assessed in clinical trials of cardiovascular outcome.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004, 164:1422–1426.
American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596–615.
Fleming A: FDA approach to the regulation of drugs for diabetes. Am Heart J 1999, 138:S338–S345.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837–853.
Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589.
Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581–2586.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.
Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 2007, 357:28–38.
The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.
ADVANCE Collaborative Group, Patel A, MacMahon S: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.
Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.
Merriam-Webster’s Collegiate Dictionary. Springfield, MA: Merriam-Webster; 2003:1258.
Temple R: Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999, 282:790–795.
Prentice R: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431–440.
Packer M, Carver JR, Rodeheffer RJ, et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991, 325:1468–1475.
Cohn JN, Goldstein SO, Greenberg BH, et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998, 339:1810–1816.
O’Connor CM, Gattis WA, Uretsky BF, et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138:78–86.
Cannon CP, McCabe CH, Wilcox RG, et al.: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000, 102:149–156.
O’sNeill WW, Serruys P, Knudtson M, et al.: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000, 342:1316–1324.
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000, 355:337–345.
Second SYMPHONY Investigators: Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001, 103:1727–1733.
Chew DP, Bhatt DL, Sapp S, Topol EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a metaanalysis of phase III multicenter randomized trials. Circulation 2001, 103:201–206.
Barter PJ, Caulfield M, Eriksson M, et al.; the ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.
Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.
Koenig W, Sund M, Frohlich M, et al.: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237–242.
Danesh J, Whincup P, Walker M, et al.: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199–204.
Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.
Gislason GH, Jacobsen S, Rasmussen JN, et al.: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006, 113:2906–2913.
Baron JA, Sandler RS, Bresalier RS, et al.: Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008, 372:1756–1764.
Fosbol EL, Gislason GH, Jacobsen S, et al.: Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009, 85:190–197.
Davi G, Patrono C: Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482–2494.
Raju NC, Eikelboom JW, Hirsh J: Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 2008, 5:766–780.
Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 1998, 338:916–917.
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440–1445.
Landmesser U, Bahlmann F, Mueller M, et al.: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356–2363.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854–865.
Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995, 18:258–268.
Standl E, Balletshofer B, Dahl B, et al.: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996, 39:1540–1545.
Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823–828.
Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405–412.
Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189–1195.
Dahabreh IJ, Economopoulos K: Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008, 5:116–120.
Friedrich JO, Beyene J, Adhikari NK: Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. BMC Res Notes 2009, 2:5.
US Food and Drug Administration: Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee Meeting, July 1 and 2, 2008. Available at http://www.fda.gov/ohrms/dockets/ac/cder08.html#EndocrinologicMetabolic. Accessed January 2009.
FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes [press release]. Silver Spring, MD: US Food and Drug Administration; December 17, 2008. Available at http://www.fda.gov/bbs/topics/NEWS/2008/NEW01928.html. Accessed January 2009.
US Food and Drug Administration: Food and Drug Administration guidance for industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Published December 2008. Available at http://www.fda.gov/Cder/Guidance/8576fnl.pdf. Accessed January 2009.
US Code of Federal Regulations, Vol 5, Title 21, Sec. 314.510: Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. Revised April 1, 2008. Available at http://www.gpoaccess.gov/cfr/retrieve.html. Accessed January 2009.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gore, M.O., McGuire, D.K. Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs. Curr Cardiol Rep 11, 258–263 (2009). https://doi.org/10.1007/s11886-009-0038-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11886-009-0038-4